Biocon (BIOCON) | Stock Overview & Key Data
Biocon Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹487.75 on December 21, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Biocon
BIOCON
|
566.52B Large-cap | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
|
Concord Biotech
CONCORDBIO
|
106.31B Mid-cap | 15.33% | 21.57% | 19.18% | 1.44% | 3.29% | -35.83% | 43.59% | 43.59% | 43.59% | 43.59% | 43.59% |
|
Blue Jet Healthcare
BLUEJET
|
69.97B Mid-cap | 11.86% | 17.17% | 41.50% | -8.00% | -4.67% | -46.26% | 31.46% | 31.46% | 31.46% | 31.46% | 31.46% |
|
Supriya Lifescience
SUPRIYA
|
51.74B Mid-cap | 3.93% | 38.73% | 66.47% | 32.20% | 28.93% | 41.71% | 283.42% | 102.02% | 102.02% | 102.02% | 102.02% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
Ownership & Short Interest
Calculate Your Biocon Investment Returns
Long-Term Investment Performance Analysis
Biocon stock price in Jul 2016 was ₹134.95, A ₹1,000.00 lump sum investment in Biocon made 9 years ago would be worth approximately ₹3,082.99 today, representing a outstanding return of 208.30%. This translates to an annualized return (CAGR) of 12.03%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BIOCON's 52-week high and low?
- In the last 52 weeks, Biocon reached a high of ₹440.40 (on May 26, 2026) and a low of ₹331.00 (on August 11, 2025).
- What is the market cap and P/E ratio for BIOCON?
- Curious about Biocon's size and valuation? Its market capitalization stands at 566.52B. When it comes to valuation, the P/E ratio (trailing twelve months) is 71.84, and the forward P/E (looking ahead) is 38.56.
- Does BIOCON pay dividends? If so, what's the yield?
- Yes, Biocon is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.26%, and the company has paid an average of ₹1.33 per share annually over the past 3 years.
- Who are Biocon's main competitors or similar companies to consider before investing?
When looking at Biocon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -20.38% -5.70% Concord Biotech
CONCORDBIO106.31B Healthcare Biotechnology -35.83% 43.59% Blue Jet Healthcare
BLUEJET69.97B Healthcare Biotechnology -46.26% 31.46% Supriya Lifescience
SUPRIYA51.74B Healthcare Biotechnology 41.71% 283.42% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 27.17% 243.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biocon Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Biocon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.66%, the Debt to Equity ratio from the most recent quarter is 50.02, and its Gross Profit Margin stands at 67.91%.
- What is the recent revenue and earnings growth for BIOCON?
- Looking at Biocon's growth, its revenue over the trailing twelve months (TTM) was INR168B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.20%, and quarterly earnings saw a YoY growth of 472.90%.
- How much of BIOCON stock is held by insiders and institutions?
- Wondering who owns Biocon stock? Company insiders (like executives and directors) hold about 54.07% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.